The Editors of Cardiovascular Diabetology's and Cardiovascular Diabetology - Endocrinology Reports explain "A significant portion of submissions to CVDB are rejected, because their topics (endocrinology) fall outside the journal’s scope. Thus, the creation of the companion journal Cardiovascular Diabetology - Endocrinology Reports addresses this gap by providing a dedicated platform for high-quality research in diabetes and all types of endocrine disorders. By expanding the editorial family, we aim to foster a broader understanding of the intricate connections between endocrine and cardiovascular systems, paving the way for translational discoveries and novel therapies." Read further details about the companion journal in the Editorial and on the Journalpage.
Cardiovascular Diabetology's new companion journal: Cardiovascular Diabetology - Endocrinology Reports
Aims and scope
Cardiovascular Diabetology considers manuscripts on all aspects of the diabetes/cardiovascular interrelationship and the metabolic syndrome; this includes clinical, genetic, experimental, pharmacological, epidemiological and molecular biology research.
Cardiovascular Diabetology appointed Dr. Pasquale Paolisso as Social Media Editor!
He will be selecting Cardiovascular Diabetology articles to be promoted on X each week based on highest quality of content and graphical abstract. Authors who want to promote their article in X are encouraged to tag Dr. Paolisso (@P_Paolisso) in their tweets.
Call for Papers: Perivascular adipose tissue: friend or foe in cardiometabolic disorders
Edited by:
Dr. Cristina Sena, PhD, University of Coimbra, Portugal
Submission Status: Open until 30 June 2025
Cardiometabolic HFpEF with focus on type 2 diabetes mellitus
Edited by:
Professor Francesco Paneni, MD, PhD, Department of Cardiology and CTEC, University Hospital and University of Zürich, Switzerland
Era Gorica, PhD, Department of Cardiology and CTEC, University Hospital and University of Zürich, Switzerland
Submission Status: Open until 20 February 2025
Articles
-
-
A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease
-
Dysregulated inflammation, oxidative stress, and protein quality control in diabetic HFpEF: unraveling mechanisms and therapeutic targets
-
Use of an insulin titration protocol based on continuous glucose monitoring in postoperative cardiac surgery patients with type 2 diabetes and prediabetes: a randomized controlled trial
-
The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
-
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
-
How hyperglycemia promotes atherosclerosis: molecular mechanisms
-
Association between insulin resistance and the development of cardiovascular disease
-
Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin
-
Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study
Editor Highlights 2024
We would like to offer you a selection of the 2024 most relevant articles, reflecting both the journal's focus on key areas and its commitment to highlighting broad and high-impact research.
Research Insights
Cardiovascular Diabetology strongly encourages authors of research articles, systematic reviews and meta analyses to add a “Research Insights” summary (< 200 words) below the abstract to include the following questions along with the responses:
- What is currently known about this topic? (max. 3 highlights)
- What is the key research question? (formatted as a question)
- What is new? (max. 3 highlights)
- How might this study influence clinical practice? (max. 1 highlight)
Please note that each highlight should be no more than 100 characters including spaces and punctuation.
Please upload this as a table.
This short and concise information helps contextualize the studies and is also helpful for editors, reviewers, readers and patients at first glance.
From the blog
Announcing the launch of In Review
Cardiovascular Diabetology, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 8.5
5-year Journal Impact Factor: 8.9
Source Normalized Impact per Paper (SNIP): 1.855
SCImago Journal Rank (SJR): 2.621Speed 2024
Submission to first editorial decision (median days): 1
Submission to acceptance (median days): 65Usage 2024
Downloads: 3,422,583
Altmetric mentions: 2,621